Physician profile
Christopher J Fontenot
NPI 1700204898
$1,378.21
in general payments reported to CMS, 2019-2025
25 companies · $395 in 2025
The $395 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29.86 · 2020: $58.58 · 2021: $143 · 2022: $278 · 2023: $286 · 2024: $189 · 2025: $395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $869.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $869.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $171.67 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Glaxosmithkline, LLC. | $144.18 | 2022-2023 | Shingrix, Arexvy |
| Organogenesis INC. | $124.86 | 2021 | |
| Pfizer INC. | $103.89 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $96.08 | 2022-2025 | |
| Astellas Pharma US INC | $91.99 | 2022 | |
| Exact Sciences Corporation | $77.65 | 2023-2024 | Cologuard Collection Kit |
| Abbvie INC. | $52.33 | 2023-2024 | |
| Sun Pharmaceutical Industries INC. | $50.95 | 2024-2025 | |
| Janssen Biotech, INC. | $47.89 | 2025 | Tremfya, Erleada |
| Novartis Pharmaceuticals Corporation | $46.74 | 2022 | |
| Mimedx Group, INC. | $42.42 | 2024-2025 | |
| Phadia US INC. | $37.28 | 2021-2022 | |
| Organon LLC | $31.26 | 2022-2025 | Nexplanon |
| Axonics, INC. | $30.54 | 2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $27.77 | 2025 | Rexulti |
| Boston Scientific Corporation | $25.56 | 2023 | Ams 800 Artificial Urinary Sphincter |
| Xeris Pharmaceuticals, INC. | $24.28 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $23.25 | 2024 | Crysvita |
| Amgen INC. | $23.25 | 2025 | Tezspire |
| Dexcom, INC. | $22.83 | 2025 | Dexcom G6 Transmitter |
| Kci USA, INC. | $22.60 | 2023 | V.A.C. Dermatac, Activ.A.C., V.A.C. Veraflo |
| Global Blood Therapeutics, INC. | $21.87 | 2022 | |
| Dynavax Technologies Corporation | $20.34 | 2025 | Heplisav-B |
| Abbott Laboratories | $16.73 | 2024 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Fontenot listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.